{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T00:23:26Z","timestamp":1792887806695,"version":"4.5.0"},"reference-count":40,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2021,8,11]],"date-time":"2021-08-11T00:00:00Z","timestamp":1628640000000},"content-version":"unspecified","delay-in-days":10,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007721","name":"Cure SMA","doi-asserted-by":"publisher","award":["ELS1819"],"award-info":[{"award-number":["ELS1819"]}],"id":[{"id":"10.13039\/100007721","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Neurol Open"],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Spinal muscular atrophy (SMA) is a motor neuron disease caused by low levels of survival motor neuron (SMN) protein. Prior work in models and patients has demonstrated electrophysiological and morphological defects at the neuromuscular junction (NMJ). Therapeutic development has resulted in clinically available therapies to increase SMN protein levels in patients and improve muscle function. Here we aimed to investigate the effect of SMN restoration (via nusinersen) on NMJ transmission in adults with SMA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Participants undergoing nusinersen treatment underwent 3\u2009Hz repetitive nerve stimulation (RNS) of the spinal accessory nerve to assess compound muscle action potential amplitude decrement. Maximum voluntary isometric contraction (MVICT), Revised Upper Limb Module (RULM), and 6\u2009min walk test (6MWT) were assessed for correlations with decrement.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Data from 13 ambulatory (7\u2009men\/6\u2009women, mean age 40\u00b111 years) and 11 non-ambulatory (3\u2009men\/8\u2009women, mean age 38\u00b112 years) participants were analysed. Cross-sectional analyses of RNS decrement were similar at 14 months of nusinersen (\u221214.2%\u00b111.5%, n=17) vs baseline (\u221211.9%\u00b18.3%, n=15) (unpaired t-test, p=0.5202). Longitudinal comparison of decrement in eight participants showed no change at 14 months (\u221213.9%\u00b16.7%) vs baseline (\u221216.9%\u00b113.4%) (paired t-test, p=0.5863). Decrement showed strong correlations with measures of MVICT, RULM and 6MWT but not age or disease duration.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Adults with SMA had significant NMJ transmission defects that were not corrected with 14 months of nusinersen treatment. NMJ defects were negatively associated with physical function, and thus may represent a promising target for additive or combinatorial treatments.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bmjno-2021-000164","type":"journal-article","created":{"date-parts":[[2021,8,12]],"date-time":"2021-08-12T16:24:55Z","timestamp":1628785495000},"page":"e000164","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":34,"title":["Persistent neuromuscular junction transmission defects in adults with spinal muscular atrophy treated with nusinersen"],"prefix":"10.1136","volume":"3","clinical-trial-number":[{"clinical-trial-number":"nct04139343","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04591678","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9889-7036","authenticated-orcid":false,"given":"W David","family":"Arnold","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Severyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songzhu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Kline","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Linsenmayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Tellez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Bartlett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Heintzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Sterling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tristan","family":"Weaver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiran","family":"Rajneesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur H M","family":"Burghes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J","family":"Kolb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bakri","family":"Elsheikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,8,12]]},"reference":[{"key":"2021081209051654000_3.2.e000164.1","doi-asserted-by":"crossref","DOI":"10.1186\/s12883-019-1244-3","article-title":"Assessment of fatigability in patients with spinal muscular atrophy: development and content validity of a set of endurance tests","volume":"19","author":"Bartels","year":"2019","journal-title":"BMC Neurol"},{"key":"2021081209051654000_3.2.e000164.2","doi-asserted-by":"publisher","DOI":"10.1006\/nbdi.1996.0010"},{"key":"2021081209051654000_3.2.e000164.3","doi-asserted-by":"publisher","DOI":"10.1038\/nrn2670"},{"key":"2021081209051654000_3.2.e000164.4","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25101"},{"key":"2021081209051654000_3.2.e000164.5","doi-asserted-by":"publisher","DOI":"10.1002\/mus.21350"},{"key":"2021081209051654000_3.2.e000164.6","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20473"},{"key":"2021081209051654000_3.2.e000164.7"},{"key":"2021081209051654000_3.2.e000164.8","doi-asserted-by":"crossref","first-page":"e2492","DOI":"10.1212\/WNL.0000000000007527","article-title":"Nusinersen in later-onset spinal muscular atrophy","volume":"92","author":"Darras","year":"2019","journal-title":"Neurology"},{"key":"2021081209051654000_3.2.e000164.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1710504"},{"key":"2021081209051654000_3.2.e000164.10","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3233\/JND-190416","article-title":"Safety and treatment effects of nusinersen in longstanding adult 5q-SMA Type 3 - a prospective observational study","volume":"6","author":"Walter","year":"2019","journal-title":"J Neuromuscul Dis"},{"key":"2021081209051654000_3.2.e000164.11","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S1474-4422(20)30037-5","article-title":"Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study","volume":"19","author":"Hagenacker","year":"2020","journal-title":"Lancet Neurol"},{"key":"2021081209051654000_3.2.e000164.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1706198"},{"key":"2021081209051654000_3.2.e000164.13","doi-asserted-by":"crossref","first-page":"e00447","DOI":"10.1002\/prp2.447","article-title":"Risdiplam distributes and increases SMN protein in both the central nervous system and peripheral organs","volume":"6","author":"Poirier","year":"2018","journal-title":"Pharmacol Res Perspect"},{"key":"2021081209051654000_3.2.e000164.14","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.8b00741"},{"key":"2021081209051654000_3.2.e000164.15","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.4434-08.2009"},{"key":"2021081209051654000_3.2.e000164.16","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182749eca"},{"key":"2021081209051654000_3.2.e000164.17","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.nmd.2017.07.007","article-title":"6MWT can identify type 3 SMA patients with neuromuscular junction dysfunction","volume":"27","author":"Pera","year":"2017","journal-title":"Neuromuscul Disord"},{"key":"2021081209051654000_3.2.e000164.18","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.1610"},{"key":"2021081209051654000_3.2.e000164.19","article-title":"Safety, tolerability, and effect of nusinersen in Non-ambulatory adults with spinal muscular atrophy","volume":"12","author":"Elsheikh","year":"2021","journal-title":"Front Neurol"},{"key":"2021081209051654000_3.2.e000164.20","article-title":"Safety, tolerability, and effect of nusinersen treatment in ambulatory adults with 5q-SMA","volume":"12","author":"Elsheikh","year":"2021","journal-title":"Front Neurol"},{"key":"2021081209051654000_3.2.e000164.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2011.12.012"},{"key":"2021081209051654000_3.2.e000164.22","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181d3e308"},{"key":"2021081209051654000_3.2.e000164.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2006.03.015"},{"key":"2021081209051654000_3.2.e000164.24","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1002\/mus.25430","article-title":"Revised upper limb module for spinal muscular atrophy: development of a new module","volume":"55","author":"Mazzone","year":"2017","journal-title":"Muscle Nerve"},{"key":"2021081209051654000_3.2.e000164.25","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/mus.26756","article-title":"Outcome measures in a cohort of ambulatory adults with spinal muscular atrophy","volume":"61","author":"Elsheikh","year":"2020","journal-title":"Muscle Nerve"},{"key":"2021081209051654000_3.2.e000164.26","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182749eca"},{"key":"2021081209051654000_3.2.e000164.27","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/mus.26769","article-title":"Nusinersen for older patients with spinal muscular atrophy: a real-world clinical setting experience","volume":"61","author":"Veerapandiyan","year":"2020","journal-title":"Muscle Nerve"},{"key":"2021081209051654000_3.2.e000164.28","doi-asserted-by":"crossref","DOI":"10.1177\/1756286420907803","article-title":"Experiences from treating seven adult 5q spinal muscular atrophy patients with nusinersen","volume":"13","author":"Jochmann","year":"2020","journal-title":"Ther Adv Neurol Disord"},{"key":"2021081209051654000_3.2.e000164.29","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3233\/JND-190453","article-title":"Prospective cohort study of nusinersen treatment in adults with spinal muscular atrophy","volume":"7","author":"Yeo","year":"2020","journal-title":"J Neuromuscul Dis"},{"key":"2021081209051654000_3.2.e000164.30","doi-asserted-by":"crossref","first-page":"e413","DOI":"10.1212\/WNL.0000000000009914","article-title":"Nusinersen in adult patients with spinal muscular atrophy: observations from a single center","volume":"95","author":"Moshe-Lilie","year":"2020","journal-title":"Neurology"},{"key":"2021081209051654000_3.2.e000164.31","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s00415-020-10223-9","article-title":"Nusinersen treatment significantly improves hand grip strength, hand motor function and MRC sum scores in adult patients with spinal muscular atrophy types 3 and 4","volume":"268","author":"De Wel","year":"2021","journal-title":"J Neurol"},{"key":"2021081209051654000_3.2.e000164.32","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2020-323822"},{"key":"2021081209051654000_3.2.e000164.33","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/ana.25930","article-title":"Yeo and Darras: extraneuronal phenotypes of spinal muscular atrophy","volume":"89","author":"Yeo","year":"2021","journal-title":"Ann Neurol"},{"key":"2021081209051654000_3.2.e000164.34","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000011230","article-title":"Correlates of fatigability in patients with spinal muscular atrophy","volume":"96","author":"Bartels","year":"2021","journal-title":"Neurology"},{"key":"2021081209051654000_3.2.e000164.35","doi-asserted-by":"publisher","DOI":"10.1172\/JCI72017"},{"key":"2021081209051654000_3.2.e000164.36","doi-asserted-by":"publisher","DOI":"10.1186\/s13041-020-0561-1"},{"key":"2021081209051654000_3.2.e000164.37","doi-asserted-by":"crossref","DOI":"10.1097\/CM9.0000000000000117","article-title":"Study on variation trend of repetitive nerve stimulation waveform in amyotrophic lateral sclerosis","volume":"132","author":"Fu","year":"2019","journal-title":"Chin Med J"},{"key":"2021081209051654000_3.2.e000164.38","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.330.7503.1314"},{"key":"2021081209051654000_3.2.e000164.39","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.nmd.2018.07.013","article-title":"Does albuterol have an effect on neuromuscular junction dysfunction in spinal muscular atrophy?","volume":"28","author":"Pera","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"2021081209051654000_3.2.e000164.40","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-019932"}],"container-title":["BMJ Neurology Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjno-2021-000164","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,7]],"date-time":"2023-01-07T06:51:16Z","timestamp":1673074276000},"score":1,"resource":{"primary":{"URL":"https:\/\/neurologyopen.bmj.com\/lookup\/doi\/10.1136\/bmjno-2021-000164"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":40,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,8,12]]},"published-print":{"date-parts":[[2021,8]]}},"alternative-id":["10.1136\/bmjno-2021-000164"],"URL":"https:\/\/doi.org\/10.1136\/bmjno-2021-000164","relation":{},"ISSN":["2632-6140"],"issn-type":[{"value":"2632-6140","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8]]}}}